The first checkpoint: three meanings of “better”
Donor human milk banking now comes into focus as a problem of judgment, not merely a sequence of handling steps. The care goal, the variability of the starting milk and the chain of safety controls all point to the same question: when a bank changes a treatment or a release rule, which kind of improvement is being claimed? A useful evaluation keeps hazard reduction, biological preservation, evidence strength and access distinct, then asks how they interact.
That distinction prevents two opposite mistakes. One is to treat any processing as a loss because it changes milk biology. The other is to treat any reduction in microbial risk as proof that the product is better in every relevant sense. A proposed treatment has to be judged against the purpose of donor human milk: protect vulnerable recipients, preserve the donor–infant relationship, maintain a usable supply and retain as much biological value as the evidence supports.
A successful batch serves several relationships
A donor-milk bank sits between people with different but connected needs. The recipient may be a preterm or low-birthweight infant who cannot receive enough mother’s own milk. The donor’s own infant must not lose access to their mother’s milk. The bank must make decisions that protect both while operating within its available screening, storage, treatment and testing capacity. A batch is successful only if it can move through that system safely enough to reach the recipient without making the conditions of donation or delivery unacceptable.
This sounds like a broad ethical statement, but it has practical consequences. A bank that increases treatment intensity may reduce some microbial hazards while changing more heat-sensitive components. A bank that accepts more donations may increase supply while overloading screening or cold storage. A bank that pools more contributions may reduce variation in the final product while increasing the amount discarded if one contribution compromises the batch. A bank that expands testing may increase confidence in one measurement while making the product too costly or wasting milk that could otherwise have been used.
These are not separate policy debates attached to a technical process. They are linked by the product pathway. If screening rejects a donor because of a relevant risk, the recipient may be better protected, but the donor also needs clear support to continue feeding their own infant. If a milk bank requires reliable freezing, the product may be safer and more stable, but donors in places without dependable electricity may find donation impossible. If a pooled batch is discarded, the decision protects recipients from a possible contamination event, but it also reduces the supply available for infants who need donor milk.
WHO’s standards make this connected view explicit. They place donor recruitment, donor support, screening, containers, storage, pooling, traceability, treatment and testing in one framework for safe, high-quality and ethical donor human milk banking. The standards do not present the framework as proof that every control has a precisely measured effect on infant outcomes. Much of the underlying evidence is low or very low certainty. Instead, the framework identifies the responsibilities that must be coordinated if safety, quality and access are to be pursued together.
The word “quality” therefore has at least two meanings in this setting. It can refer to the condition of a particular sample—its microbial content, nutrient composition or bioactive activity. It can also refer to the reliability of the system that produced and delivered it: whether the donor was protected, the batch can be traced, the cold chain was maintained and the release decision was based on a meaningful test.